Application Nr Approved Date Route Status External Links
ANDA206811 None Oral None Google , Wikipedia , PubMed , DailyMed , Raw OpenFDA , ECHA , ToxNet , JECFA , FAO , 21 CFR

Indications and Purposes

1 Indications And Usage Dalfampridine Extended-Release Tablets Are Indicated As A Treatment To Improve Walking In Adult Patients With Multiple Sclerosis (Ms). This Was Demonstrated By An Increase In Walking Speed [See Clinical Studies (14) ]. Dalfampridine Extended-Release Tablets Are A Potassium Channel Blocker Indicated To Improve Walking In Adult Patients With Multiple Sclerosis (Ms). This Was Demonstrated By An Increase In Walking Speed (1, 14 ).

All Formulated Excipients (0 Total)

None

Active Ingredients ( 1 Total)

Name Structure ZINC ID(s)
1. Dalfampridine DALFAMPRIDINE ZINC599985

Comments